Table 1. Fourteen topics of major clinical research advances in gynecologic cancer in 2015.

Site of cancer	Topic		Reference
Ovary	1. Prevention and screening of ovarian cancer		[2,4,5,12]
	2. Update of neoadjuvant chemotherapy in ovarian cancer: right therapy to right person		[15]
	3. Personalized therapy for the best possible chance of survival in ovarian cancer		[21,22,23,24]
	4. Fifth Ovarian Cancer Consensus Conference in Tokyo
	5. Immunotherapy update: anti-PD-1/PD-L1 antibody in ovarian cancer		[25,26]
Uterine cervix	6. HPV vaccine update: two dose, 9-valent, therapeutic vaccine		[28,36,42]
Uterine corpus	7. Old age as a reason for abandoning power morcellation in presumed fibroids		[43,44,45]
	8. Hormone therapies and endometrial cancer risk		[48,49]
	9. Trabectedin: another FDA-approved option for leiomyosarcoma		[56]
	10. Endometrial cancer and Lynch syndrome		[58,59]
	11. Radiation therapy in endometrial cancer: ESMO-ESGO-ESTRO consensus conference guidelines		[63,64,65]
Others	12. Vulvar cancer adjuvant therapy		[71]
	13. Targeted therapy update in gynecologic cancer
		1) Update of anti-angiogenic drugs in ovarian cancer	[74,75,76]
		2) Other promising targeting agents in ovarian cancer	[81,82,84,85]
		3) Update of targeted therapy in cervical and endometrial cancer	[88,90,91]
Female breast	14. Breast cancer
		1) Palbociclib in hormone-receptor-positive advanced breast cancer	[93]
		2) Oncotype DX Recurrence Score in low-risk breast cancer	[97]
		3) Regional nodal irradiation to internal mammary, supraclavicular, and axillary lymph nodes in breast cancer	[98,99]
		4) Cavity shave margins in breast cancer	[100]

ESGO, European Society of Gynecologic Oncology; ESMO, European Society of Medical Oncology; ESTRO, European Society for Radiotherapy and Oncology; FDA, the Food and Drug Administration; HPV, human papillomavirus; PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1.